oxidopamine has been researched along with Astrocytosis in 34 studies
Oxidopamine: A neurotransmitter analogue that depletes noradrenergic stores in nerve endings and induces a reduction of dopamine levels in the brain. Its mechanism of action is related to the production of cytolytic free-radicals.
oxidopamine : A benzenetriol that is phenethylamine in which the hydrogens at positions 2, 4, and 5 on the phenyl ring are replaced by hydroxy groups. It occurs naturally in human urine, but is also produced as a metabolite of the drug DOPA (used for the treatment of Parkinson's disease).
| Excerpt | Relevance | Reference |
|---|---|---|
| "Riluzole is a neuroprotective drug used in the treatment of motor neurone disease." | 5.38 | Riluzole neuroprotection in a Parkinson's disease model involves suppression of reactive astrocytosis but not GLT-1 regulation. ( Carbone, M; Duty, S; Rattray, M, 2012) |
| "Reactive astrogliosis and the over-production of proinflammatory factors are key pathogenetic processes in Parkinson's disease (PD)." | 1.72 | High-Frequency Repetitive Transcranial Magnetic Stimulation Regulates Astrocyte Activation by Modulating the Endocannabinoid System in Parkinson's Disease. ( Bai, Y; Du, W; Gao, F; Jiang, X; Kang, X; Liu, X; Mou, X; Pang, J; Sun, X; Yuan, H; Zhang, B; Zhao, C; Zhao, R, 2022) |
| "In addition, indices of astrogliosis, microgliosis, as well as oxidative stress in the striatum were determined." | 1.51 | Effectiveness of Fragment C Domain of Tetanus Toxin and Pramipexole in an Animal Model of Parkinson's Disease. ( Aguilera, J; Limón, ID; Martínez, I; Mendieta, L; Montes, S; Parra, I; Patricio, F; Pérez-Severiano, F; Tizabi, Y, 2019) |
| "Parkinson's disease is accompanied by nonmotor symptoms including cognitive impairment, which precede the onset of motor symptoms in patients and are regulated by dopamine (DA) receptors and the mesocorticolimbic pathway." | 1.48 | Acetyl-L-Carnitine via Upegulating Dopamine D1 Receptor and Attenuating Microglial Activation Prevents Neuronal Loss and Improves Memory Functions in Parkinsonian Rats. ( Mishra, A; Shukla, R; Shukla, S; Singh, S; Srivastava, N, 2018) |
| "Sesamin is a lignan compound and the active constituent of sesame oil with antioxidant and anti-inflammatory properties." | 1.46 | Sesamin imparts neuroprotection against intrastriatal 6-hydroxydopamine toxicity by inhibition of astroglial activation, apoptosis, and oxidative stress. ( Baluchnejadmojarad, T; Ghalami, J; Mansouri, M; Mokhtari, Z; Roghani, M, 2017) |
| "Parkinson's disease is a slowly progressing neurodegenerative disorder caused by loss of dopaminergic neurons in the substantia nigra (SN), leading to severe impairment in motor and non-motor functions." | 1.43 | 6-hydroxydopamine-induced Parkinson's disease-like degeneration generates acute microgliosis and astrogliosis in the nigrostriatal system but no bioluminescence imaging-detectable alteration in adult neurogenesis. ( Collmann, FM; Dollé, F; Faber, C; Faust, A; Fricke, IB; Hermann, S; Jacobs, AH; Kuhlmann, MT; Schäfers, K; Schwamborn, JC; Viel, T; Vrachimis, A; Wachsmuth, L; Worlitzer, MM, 2016) |
| "This astrocytosis was severe and had a specific profile which included some (e." | 1.43 | The astrocytic response to the dopaminergic denervation of the striatum. ( Morales, I; Rodriguez, M; Rodriguez-Sabate, C; Sanchez, A, 2016) |
| " Three or 14 days after lesion, rats were dosed with XPro®1595 (10 mg/kg in saline, subcutaneous) every third day for 35 days." | 1.40 | Peripheral administration of the selective inhibitor of soluble tumor necrosis factor (TNF) XPro®1595 attenuates nigral cell loss and glial activation in 6-OHDA hemiparkinsonian rats. ( Barnum, CJ; Chang, J; Chen, X; Chung, J; Grigoryan, N; Tansey, MG; Tesi, RJ; Williams, M, 2014) |
| "Riluzole is a neuroprotective drug used in the treatment of motor neurone disease." | 1.38 | Riluzole neuroprotection in a Parkinson's disease model involves suppression of reactive astrocytosis but not GLT-1 regulation. ( Carbone, M; Duty, S; Rattray, M, 2012) |
| "Reactive gliosis, which occurs in response to damage to the central nervous system, has been recognized for years but is not yet understood." | 1.30 | A culture model of reactive astrocytes: increased nerve growth factor synthesis and reexpression of cytokine responsiveness. ( Nishiyama, N; Schwartz, JP; Wu, VW, 1998) |
| "In contrast there was a marked gliosis in the striatum surrounding foetal grafts which was unaffected by chronic treatment with L-DOPA and carbidopa." | 1.28 | Motor function, graft survival and gliosis in rats with 6-OHDA lesions and foetal ventral mesencephalic grafts chronically treated with L-dopa and carbidopa. ( Blunt, SB; Jenner, P; Marsden, CD, 1992) |
| "As a model of reactive gliosis secondary to degenerative disorders, 6-hydroxydopamine (6-OHDA) lesion of the substantia nigra in the rat was performed." | 1.27 | Identification of a human glial fibrillary acidic protein cDNA: a tool for the molecular analysis of reactive gliosis in the mammalian central nervous system. ( Boularand, S; De Vitry, F; Faucon Biguet, N; Mallet, J; Privat, A; Rataboul, P; Vernier, P, 1988) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (2.94) | 18.7374 |
| 1990's | 5 (14.71) | 18.2507 |
| 2000's | 11 (32.35) | 29.6817 |
| 2010's | 16 (47.06) | 24.3611 |
| 2020's | 1 (2.94) | 2.80 |
| Authors | Studies |
|---|---|
| Kang, X | 1 |
| Zhang, B | 1 |
| Du, W | 1 |
| Zhao, R | 1 |
| Liu, X | 1 |
| Bai, Y | 1 |
| Jiang, X | 1 |
| Pang, J | 1 |
| Zhao, C | 1 |
| Mou, X | 1 |
| Gao, F | 1 |
| Yuan, H | 1 |
| Sun, X | 1 |
| Zhang, W | 1 |
| Zhang, L | 1 |
| Liu, L | 1 |
| Wang, X | 1 |
| Chen, HH | 1 |
| Chang, PC | 1 |
| Wey, SP | 1 |
| Chen, PM | 1 |
| Chen, C | 1 |
| Chan, MH | 1 |
| Patricio, F | 1 |
| Parra, I | 1 |
| Martínez, I | 1 |
| Pérez-Severiano, F | 1 |
| Montes, S | 1 |
| Aguilera, J | 1 |
| Limón, ID | 2 |
| Tizabi, Y | 1 |
| Mendieta, L | 1 |
| Carmo, MR | 1 |
| Menezes, AP | 1 |
| Nunes, AC | 1 |
| Pliássova, A | 1 |
| Rolo, AP | 1 |
| Palmeira, CM | 1 |
| Cunha, RA | 1 |
| Canas, PM | 1 |
| Andrade, GM | 1 |
| Barnum, CJ | 1 |
| Chen, X | 1 |
| Chung, J | 1 |
| Chang, J | 1 |
| Williams, M | 1 |
| Grigoryan, N | 1 |
| Tesi, RJ | 1 |
| Tansey, MG | 2 |
| Ramírez-García, G | 1 |
| Palafox-Sánchez, V | 1 |
| Morales, I | 2 |
| Sanchez, A | 2 |
| Rodriguez-Sabate, C | 2 |
| Rodriguez, M | 2 |
| Tristão, FS | 1 |
| Lazzarini, M | 1 |
| Martin, S | 1 |
| Amar, M | 1 |
| Stühmer, W | 1 |
| Kirchhoff, F | 1 |
| Gomes, LA | 1 |
| Lanfumey, L | 1 |
| Prediger, RD | 1 |
| Sepulveda, JE | 1 |
| Del-Bel, EA | 1 |
| Raisman-Vozari, R | 1 |
| Kiasalari, Z | 1 |
| Khalili, M | 1 |
| Baluchnejadmojarad, T | 2 |
| Roghani, M | 2 |
| Fricke, IB | 1 |
| Viel, T | 1 |
| Worlitzer, MM | 1 |
| Collmann, FM | 1 |
| Vrachimis, A | 1 |
| Faust, A | 1 |
| Wachsmuth, L | 1 |
| Faber, C | 1 |
| Dollé, F | 1 |
| Kuhlmann, MT | 1 |
| Schäfers, K | 1 |
| Hermann, S | 1 |
| Schwamborn, JC | 1 |
| Jacobs, AH | 1 |
| Yelkenli, İH | 1 |
| Ulupinar, E | 1 |
| Korkmaz, OT | 1 |
| Şener, E | 1 |
| Kuş, G | 1 |
| Filiz, Z | 1 |
| Tunçel, N | 1 |
| Singh, S | 1 |
| Mishra, A | 1 |
| Srivastava, N | 1 |
| Shukla, R | 1 |
| Shukla, S | 1 |
| Mansouri, M | 1 |
| Ghalami, J | 1 |
| Mokhtari, Z | 1 |
| Nagel, F | 1 |
| Bähr, M | 1 |
| Dietz, GP | 1 |
| Carbone, M | 1 |
| Duty, S | 1 |
| Rattray, M | 1 |
| Wachter, B | 1 |
| Schürger, S | 1 |
| Schmid, A | 1 |
| Gröger, A | 1 |
| Sadler, R | 1 |
| Speidel, A | 1 |
| Rolinger, J | 1 |
| Pichler, BJ | 1 |
| Berg, D | 1 |
| Wagner, HJ | 1 |
| von Ameln-Mayerhofer, A | 1 |
| Küppers, E | 1 |
| Chadi, G | 1 |
| Gomide, VC | 1 |
| Muñoz, AM | 1 |
| Rey, P | 1 |
| Parga, J | 1 |
| Guerra, MJ | 1 |
| Labandeira-Garcia, JL | 1 |
| Nakagawa, T | 1 |
| Yabe, T | 2 |
| Schwartz, JP | 3 |
| McCoy, MK | 1 |
| Martinez, TN | 1 |
| Ruhn, KA | 1 |
| Szymkowski, DE | 1 |
| Smith, CG | 1 |
| Botterman, BR | 1 |
| Tansey, KE | 1 |
| Venneti, S | 1 |
| Lopresti, BJ | 1 |
| Wang, G | 1 |
| Slagel, SL | 1 |
| Mason, NS | 1 |
| Mathis, CA | 1 |
| Fischer, ML | 1 |
| Larsen, NJ | 1 |
| Mortimer, AD | 1 |
| Hastings, TG | 1 |
| Smith, AD | 1 |
| Zigmond, MJ | 1 |
| Suhara, T | 1 |
| Higuchi, M | 1 |
| Wiley, CA | 1 |
| Iczkiewicz, J | 1 |
| Rose, S | 1 |
| Jenner, P | 2 |
| Brown, EE | 1 |
| Fibiger, HC | 1 |
| Takeda, A | 1 |
| Sawashita, J | 1 |
| Takefuta, S | 1 |
| Okada, S | 1 |
| Wu, VW | 1 |
| Nishiyama, N | 2 |
| Nomura, T | 1 |
| Rosenthal, ES | 1 |
| Krzan, M | 1 |
| He, Y | 1 |
| Appel, S | 1 |
| Le, W | 1 |
| Ikeda, K | 1 |
| Kurokawa, M | 1 |
| Aoyama, S | 1 |
| Kuwana, Y | 1 |
| Cicchetti, F | 1 |
| Brownell, AL | 1 |
| Williams, K | 1 |
| Chen, YI | 1 |
| Livni, E | 1 |
| Isacson, O | 1 |
| Matsuda, S | 1 |
| Saito, H | 1 |
| Blunt, SB | 1 |
| Marsden, CD | 1 |
| Rataboul, P | 1 |
| Faucon Biguet, N | 1 |
| Vernier, P | 1 |
| De Vitry, F | 1 |
| Boularand, S | 1 |
| Privat, A | 1 |
| Mallet, J | 1 |
34 other studies available for oxidopamine and Astrocytosis
| Article | Year |
|---|---|
High-Frequency Repetitive Transcranial Magnetic Stimulation Regulates Astrocyte Activation by Modulating the Endocannabinoid System in Parkinson's Disease.
Topics: Animals; Astrocytes; Endocannabinoids; Gliosis; Oxidopamine; Parkinson Disease; Rats; Transcranial M | 2022 |
Time course study of fractional anisotropy in the substantia nigra of a parkinsonian rat model induced by 6-OHDA.
Topics: Animals; Apomorphine; Diffusion Tensor Imaging; Disease Progression; Dopamine Agonists; Gliosis; Imm | 2017 |
Therapeutic effects of honokiol on motor impairment in hemiparkinsonian mice are associated with reversing neurodegeneration and targeting PPARγ regulation.
Topics: Animals; Biphenyl Compounds; Gliosis; Lignans; Longevity; Male; Mice; Motor Activity; NADPH Oxidases | 2018 |
Effectiveness of Fragment C Domain of Tetanus Toxin and Pramipexole in an Animal Model of Parkinson's Disease.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antioxidants; Antiparkinson Agents; Astrocytes; Co | 2019 |
The P2X7 receptor antagonist Brilliant Blue G attenuates contralateral rotations in a rat model of Parkinsonism through a combined control of synaptotoxicity, neurotoxicity and gliosis.
Topics: Animals; Avoidance Learning; Brain; Cell Line, Tumor; Disease Models, Animal; Exploratory Behavior; | 2014 |
Peripheral administration of the selective inhibitor of soluble tumor necrosis factor (TNF) XPro®1595 attenuates nigral cell loss and glial activation in 6-OHDA hemiparkinsonian rats.
Topics: Animals; Blood-Brain Barrier; Cell Count; Disease Models, Animal; Dopaminergic Neurons; Encephalitis | 2014 |
Nitrosative and cognitive effects of chronic L-DOPA administration in rats with intra-nigral 6-OHDA lesion.
Topics: Animals; Antiparkinson Agents; Astrocytes; Carbidopa; Corpus Striatum; Gliosis; Levodopa; Male; Maze | 2015 |
The degeneration of dopaminergic synapses in Parkinson's disease: A selective animal model.
Topics: Animals; Astrocytes; Corpus Striatum; Disease Models, Animal; Dopaminergic Neurons; Gliosis; Infusio | 2015 |
CX3CR1 Disruption Differentially Influences Dopaminergic Neuron Degeneration in Parkinsonian Mice Depending on the Neurotoxin and Route of Administration.
Topics: Administration, Intranasal; Animals; Astrocytes; Corpus Striatum; CX3C Chemokine Receptor 1; Dopamin | 2016 |
Protective Effect of Oral Hesperetin Against Unilateral Striatal 6-Hydroxydopamine Damage in the Rat.
Topics: Administration, Oral; Animals; Apoptosis; Corpus Striatum; Glial Fibrillary Acidic Protein; Gliosis; | 2016 |
6-hydroxydopamine-induced Parkinson's disease-like degeneration generates acute microgliosis and astrogliosis in the nigrostriatal system but no bioluminescence imaging-detectable alteration in adult neurogenesis.
Topics: Animals; Astrocytes; Cell Proliferation; Corpus Striatum; Disease Models, Animal; Dopaminergic Neuro | 2016 |
Modulation of Corpus Striatal Neurochemistry by Astrocytes and Vasoactive Intestinal Peptide (VIP) in Parkinsonian Rats.
Topics: Animals; Astrocytes; Corpus Striatum; gamma-Aminobutyric Acid; Glial Fibrillary Acidic Protein; Glio | 2016 |
The astrocytic response to the dopaminergic denervation of the striatum.
Topics: Animals; Astrocytes; Cell Differentiation; Cell Line; Cell Proliferation; Corpus Striatum; Denervati | 2016 |
Acetyl-L-Carnitine via Upegulating Dopamine D1 Receptor and Attenuating Microglial Activation Prevents Neuronal Loss and Improves Memory Functions in Parkinsonian Rats.
Topics: Acetylcarnitine; Animals; Cell Line; Dopaminergic Neurons; Excitatory Amino Acid Transporter 2; Glio | 2018 |
Sesamin imparts neuroprotection against intrastriatal 6-hydroxydopamine toxicity by inhibition of astroglial activation, apoptosis, and oxidative stress.
Topics: Animals; Apoptosis; Astrocytes; Behavior, Animal; Caspase 3; Dioxoles; Gliosis; Lignans; Male; Malon | 2017 |
Tyrosine hydroxylase-positive amacrine interneurons in the mouse retina are resistant against the application of various parkinsonian toxins.
Topics: Amacrine Cells; Animals; Astrocytes; Cell Death; Cell Survival; Chromatography, High Pressure Liquid | 2009 |
Riluzole neuroprotection in a Parkinson's disease model involves suppression of reactive astrocytosis but not GLT-1 regulation.
Topics: Animals; Astrocytes; Corpus Striatum; Disease Models, Animal; Dopaminergic Neurons; Excitatory Amino | 2012 |
6-Hydroxydopamine leads to T2 hyperintensity, decreased claudin-3 immunoreactivity and altered aquaporin 4 expression in the striatum.
Topics: Animals; Aquaporin 4; Blood-Brain Barrier; Blotting, Western; Brain; Brain Chemistry; Catecholamines | 2012 |
FGF-2 and S100beta immunoreactivities increase in reactive astrocytes, but not in microglia, in ascending dopamine pathways following a striatal 6-OHDA-induced partial lesion of the nigrostriatal system.
Topics: Animals; Antigens, Surface; Astrocytes; Cell Communication; Denervation; Disease Models, Animal; Dop | 2004 |
Glial overexpression of heme oxygenase-1: a histochemical marker for early stages of striatal damage.
Topics: 5,7-Dihydroxytryptamine; Afferent Pathways; Animals; Astrocytes; Basal Ganglia Diseases; Biomarkers; | 2005 |
Gene expression profiles of reactive astrocytes cultured from dopamine-depleted striatum.
Topics: Animals; Antibodies; Astrocytes; Corpus Striatum; Disease Models, Animal; Dopamine; Down-Regulation; | 2005 |
Blocking soluble tumor necrosis factor signaling with dominant-negative tumor necrosis factor inhibitor attenuates loss of dopaminergic neurons in models of Parkinson's disease.
Topics: Amphetamine; Animals; Cell Death; Cells, Cultured; Coculture Techniques; Disease Models, Animal; Dop | 2006 |
A comparison of the high-affinity peripheral benzodiazepine receptor ligands DAA1106 and (R)-PK11195 in rat models of neuroinflammation: implications for PET imaging of microglial activation.
Topics: Acetamides; Animals; Binding, Competitive; Brain; Disease Models, Animal; Encephalitis; Gliosis; Iso | 2007 |
Osteopontin expression in activated glial cells following mechanical- or toxin-induced nigral dopaminergic cell loss.
Topics: Animals; Cell Count; Cell Death; Dopamine; Ectodysplasins; Glial Fibrillary Acidic Protein; Gliosis; | 2007 |
Differential effects of excitotoxic lesions of the amygdala on cocaine-induced conditioned locomotion and conditioned place preference.
Topics: Amygdala; Animals; Cocaine; Conditioning, Operant; Gliosis; Male; Motor Activity; Oxidopamine; Quino | 1993 |
Distribution of zinc in the substantia nigra of rats treated with 6-hydroxydopamine.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adrenergic Agents; Animals; Autoradiography; Blood-Brain Barrier; Ch | 1998 |
A culture model of reactive astrocytes: increased nerve growth factor synthesis and reexpression of cytokine responsiveness.
Topics: Animals; Astrocytes; Cells, Cultured; Cerebral Cortex; Corpus Striatum; Gene Expression Regulation; | 1998 |
PSA-NCAM distinguishes reactive astrocytes in 6-OHDA-lesioned substantia nigra from those in the striatal terminal fields.
Topics: Animals; Antigens; Astrocytes; Biomarkers; Cells, Cultured; Corpus Striatum; Denervation; Dopamine; | 2000 |
Minocycline inhibits microglial activation and protects nigral cells after 6-hydroxydopamine injection into mouse striatum.
Topics: Animals; Anti-Bacterial Agents; Cell Death; Disease Models, Animal; Gliosis; Immunohistochemistry; M | 2001 |
Neuroprotection by adenosine A2A receptor blockade in experimental models of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; Animals; Antineoplastic A | 2002 |
Neuroinflammation of the nigrostriatal pathway during progressive 6-OHDA dopamine degeneration in rats monitored by immunohistochemistry and PET imaging.
Topics: Animals; Antigens, CD; Antigens, Neoplasm; Antigens, Surface; Antineoplastic Agents; Avian Proteins; | 2002 |
Basic fibroblast growth factor ameliorates rotational behavior of substantia nigral-transplanted rats with lesions of the dopaminergic nigrostriatal neurons.
Topics: Animals; Apomorphine; Behavior, Animal; Corpus Striatum; Disease Models, Animal; Female; Fibroblast | 1992 |
Motor function, graft survival and gliosis in rats with 6-OHDA lesions and foetal ventral mesencephalic grafts chronically treated with L-dopa and carbidopa.
Topics: Animals; Apomorphine; Brain Tissue Transplantation; Carbidopa; Dextroamphetamine; Female; Fetal Tiss | 1992 |
Identification of a human glial fibrillary acidic protein cDNA: a tool for the molecular analysis of reactive gliosis in the mammalian central nervous system.
Topics: Amino Acid Sequence; Animals; Astrocytoma; Base Sequence; DNA; Glial Fibrillary Acidic Protein; Glio | 1988 |